Jagsonpal Historical Cash Flow

JAGSNPHARM   636.65  9.80  1.52%   
Analysis of Jagsonpal Pharmaceuticals cash flow over time is an excellent tool to project Jagsonpal Pharmaceuticals future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Free Cash Flow of 366.6 M or Change In Working Capital of 58.2 M as it is a great indicator of Jagsonpal Pharmaceuticals ability to facilitate future growth, repay debt on time or pay out dividends.
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Jagsonpal Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Jagsonpal Pharmaceuticals is a good buy for the upcoming year.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jagsonpal Pharmaceuticals Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Jagsonpal Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in Jagsonpal balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Jagsonpal's non-liquid assets can be easily converted into cash.

Jagsonpal Pharmaceuticals Cash Flow Chart

As of now, Jagsonpal Pharmaceuticals' Change In Working Capital is increasing as compared to previous years. The Jagsonpal Pharmaceuticals' current Begin Period Cash Flow is estimated to increase to about 179.7 M, while Other Cashflows From Financing Activities is projected to decrease to (15.2 M).

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Capital Expenditures

Capital Expenditures are funds used by Jagsonpal Pharmaceuticals to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Jagsonpal Pharmaceuticals operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.
Most accounts from Jagsonpal Pharmaceuticals' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Jagsonpal Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jagsonpal Pharmaceuticals Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
As of now, Jagsonpal Pharmaceuticals' Change In Working Capital is increasing as compared to previous years. The Jagsonpal Pharmaceuticals' current Begin Period Cash Flow is estimated to increase to about 179.7 M, while Other Cashflows From Financing Activities is projected to decrease to (15.2 M).

Jagsonpal Pharmaceuticals cash flow statement Correlations

0.260.460.43-0.25-0.320.220.20.18-0.04-0.160.380.210.47-0.18-0.220.11
0.260.190.65-0.44-0.040.070.12-0.260.40.38-0.070.06-0.120.430.530.04
0.460.190.60.1-0.43-0.18-0.630.640.250.10.160.40.560.13-0.620.51
0.430.650.6-0.18-0.560.03-0.11-0.030.360.450.160.230.170.28-0.040.16
-0.25-0.440.1-0.18-0.47-0.38-0.480.480.64-0.07-0.22-0.52-0.320.41-0.19-0.16
-0.32-0.04-0.43-0.56-0.470.530.25-0.37-0.51-0.350.170.070.15-0.240.28-0.13
0.220.07-0.180.03-0.380.530.37-0.5-0.32-0.30.71-0.030.4-0.120.14-0.41
0.20.12-0.63-0.11-0.480.250.37-0.6-0.38-0.010.10.02-0.2-0.250.46-0.41
0.18-0.260.64-0.030.48-0.37-0.5-0.60.27-0.32-0.290.080.110.16-0.680.26
-0.040.40.250.360.64-0.51-0.32-0.380.270.24-0.29-0.49-0.440.80.27-0.14
-0.160.380.10.45-0.07-0.35-0.3-0.01-0.320.24-0.070.01-0.030.290.330.46
0.38-0.070.160.16-0.220.170.710.1-0.29-0.29-0.070.240.76-0.16-0.070.09
0.210.060.40.23-0.520.07-0.030.020.08-0.490.010.240.48-0.54-0.40.5
0.47-0.120.560.17-0.320.150.4-0.20.11-0.44-0.030.760.48-0.32-0.460.5
-0.180.430.130.280.41-0.24-0.12-0.250.160.80.29-0.16-0.54-0.320.37-0.24
-0.220.53-0.62-0.04-0.190.280.140.46-0.680.270.33-0.07-0.4-0.460.37-0.24
0.110.040.510.16-0.16-0.13-0.41-0.410.26-0.140.460.090.50.5-0.24-0.24
Click cells to compare fundamentals

Jagsonpal Pharmaceuticals Account Relationship Matchups

Jagsonpal Pharmaceuticals cash flow statement Accounts

201920202021202220232024 (projected)
Change To Inventory33.7M(4.0M)(176K)90.7M53.1M55.8M
Change In Cash(4.6M)191.3M(329.1M)(114.7M)17.1M17.9M
Free Cash Flow91.8M277.5M51.3M463.4M349.2M366.6M
Change In Working Capital42.5M115.9M(171.3M)98.7M55.4M58.2M
Begin Period Cash Flow385.3M398.1M589.4M225.3M110.5M179.7M
Other Cashflows From Financing Activities3.7M(5.1M)(18.2M)(3.2M)(14.5M)(15.2M)
Depreciation11.3M10.9M15.3M12.1M16.6M15.0M
Other Non Cash Items(35.5M)(63.3M)(61.2M)(2.4M)(78.1M)(74.2M)
Capital Expenditures20.7M4.7M4.7M3.2M2.5M2.4M
Total Cash From Operating Activities112.5M282.2M56.0M466.5M351.7M369.2M
Net Income94.1M218.7M273.2M348.1M224.6M116.5M
Total Cash From Financing Activities(9.4M)(68.3M)(123.0M)(4.6M)(89.1M)(93.6M)
End Period Cash Flow380.7M589.4M260.3M110.5M127.6M184.2M
Dividends Paid13.1M26.2M104.8M0.0131.0M137.5M
Change To Account Receivables(7.0M)87.9M(29.6M)(55.6M)91.5M96.1M
Net Borrowings(45.2M)8.8M(67.9M)(3.2M)(2.9M)(3.0M)
Total Cashflows From Investing Activities(110.7M)(22.6M)(262.1M)(576.7M)(519.0M)(493.1M)
Change To Operating Activities27.3M(57.9M)(114.9M)83.3M75.0M78.7M
Other Cashflows From Investing Activities21.7M23.8M27.1M34.3M73.7M77.4M
Change To Netincome(19.5M)(15.2M)16.1M88.8M102.2M107.3M
Change To Liabilities(3.7M)182.9M8.8M(19.6M)(22.6M)(21.4M)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Jagsonpal Stock

The Cash Flow Statement is a financial statement that shows how changes in Jagsonpal balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Jagsonpal's non-liquid assets can be easily converted into cash.